You won't find a more prototypical blue-chip than health care giant Johnson & Johnson ( JNJ). The $227 billion firm has its hands in everything from everything from consumer products like Band-Aid brand bandages to pharmaceuticals and medical devices. Funds added onto their health care buying spree with an additional 7.5 million shares of JNJ in the first quarter. >>5 Consumer Stocks Ready to Push Higher Even though Johnson & Johnson's most consumer-facing business is found on pharmacy shelves, the bulk of the firm's net income is earned behind the pharmacy counter. JNJ offers a big benefit over pure-play pharma firms, however: the consumer and medical device segments offer investors diversification that few big pharma names can match -- especially as patent drop-offs (AbbVie's biggest detractor) plague valuations in the industry. A strong pipeline of new drug offerings should smooth out effects from patent expirations in the next few years. Johnson & Johnson's balance sheet is in stellar shape right now. While the company only has around $5 billion in net cash after parting with considerable liquidity to acquire Synthes, the firm still has ample cash on hand to pay out its 2.9% dividend yield and to cover any other financial speed bumps in the road.